Value through Innovation27 July 2016

What is a lay summary?

To view this video in other translations click on the language below:
Chinese (simplified)
Chinese (traditional)
Portuguese (Brazilian)

Clinical Study Results

  • Doramapimod - Crohn Disease
    Clinical Study Number 1175.12
    Study Indication Crohn Disease
    Product Doramapimod
    Generic Name Doramapimod
    Lab Code
    Clinical Phase IIa
    Study Title

    A randomised, double-blind, placebo-controlled, four parallel groups, dose finding study of BIRB 796 BS (10, 20 and 30 mg) administered twice a day orally over 8 weeks in patients with moderate to servere Crohn´s disease followed by a 18 weeks treatment extension in patients with Clinical Remission or Clinical Response after 8 weeks treatment with the respective dose of BIRB 796 BS

    Study Document
    Trial synopsis 1175.12 english
    Trial synopsis 1175.12_ext english
  • Risankizumab - Crohn Disease
    Clinical Study Number 1311.6
    Study Indication Crohn Disease
    Product Risankizumab
    Generic Name Risankizumab
    Lab Code BI 655066
    Clinical Phase II
    Study Title

    A Phase 2, Multicenter, Randomized, Double-Blind, Multiple Dose, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of BI 655066 (Risankizumab), an IL-23 p19 Antagonist Monoclonal Antibody, in Patients With Moderately to Severely Active Crohn's Disease Who Are Naïve to or Were Previously Treated With Anti-TNF Therapy

    Study Document
    Trial synopsis 1311.6 English